

Attorney Docket No.: DEX-0176  
Inventors: Ali and Cafferkey  
Serial No.: 09/787,844  
Filing Date: August 6, 2001  
Page 2

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1 (original): A method for diagnosing the presence of a gynecologic cancer or testicular cancer in a patient comprising:

(a) measuring levels of CSG in cells, tissues or bodily fluids in a patient; and

(b) comparing the measured levels of CSG with levels of CSG in cells, tissues or bodily fluids from a normal human control, wherein a change in measured levels of CSG in said patient versus normal human control is associated with the presence of a gynecologic cancer or testicular cancer.

Claim 2 (original): A method of diagnosing metastases of a gynecologic cancer or testicular cancer in a patient comprising:

(a) identifying a patient having a selected cancer that is not known to have metastasized;

(b) measuring CSG levels in a sample of cells, tissues, or bodily fluid from said patient; and

(c) comparing the measured CSG levels with levels of CSG in cells, tissue, or bodily fluid of a normal human control, wherein

Attorney Docket No.: DEX-0176  
Inventors: Ali and Cafferkey  
Serial No.: 09/787,844  
Filing Date: August 6, 2001  
Page 3

an increase in measured CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Claim 3 (original): A method of staging a gynecologic cancer or testicular cancer in a patient having a gynecologic cancer or testicular cancer comprising:

- (a) identifying a patient having the cancer;
- (b) measuring CSG levels in a sample of cells, tissue, or bodily fluid from said patient; and
- (c) comparing measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control sample, wherein an increase in measured CSG levels in said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the measured CSG levels is associated with a cancer which is regressing or in remission.

Claim 4 (original): A method of monitoring a gynecologic cancer or testicular cancer in a patient for the onset of metastasis comprising:

- (a) identifying a patient having a gynecologic cancer or testicular cancer that is not known to have metastasized;
- (b) periodically measuring levels of CSG in samples of cells, tissues, or bodily fluid from said patient for CSG; and

Attorney Docket No.: DEX-0176  
Inventors: Ali and Cafferkey  
Serial No.: 09/787,844  
Filing Date: August 6, 2001  
Page 4

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Claim 5 (original): A method of monitoring the change in stage of a gynecologic cancer or testicular cancer in a patient comprising:

(a) identifying a patient having a gynecologic cancer or testicular cancer;

(b) periodically measuring levels of CSG in cells, tissues, or bodily fluid from said patient for CSG; and

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

Claim 6 (original): The method of claim 1, 2, 3, 4 or 5 wherein the CSG comprises SEQ ID NO:1.

Claim 7 (original): An antibody against a CSG wherein said

Attorney Docket No.: DEX-0176  
Inventors: Ali and Cafferkey  
Serial No.: 09/787,844  
Filing Date: August 6, 2001  
Page 5

CSG comprises SEQ ID NO:1.

Claim 8 (currently amended): A method of imaging a gynecologic cancer ~~or testicular cancer in a patient~~ comprising ~~contacting a cell with administering to the patient~~ an antibody ~~of claim 7 which specifically binds a Pro104 polypeptide.~~

Claim 9 (currently amended): The method of claim 8 wherein said antibody is labeled with a fluorescent reagent, an enzyme, a paramagnetic ion ions or a radioisotope.

Claim 10-11 (canceled)

Claim 12 (new): The method of claim 8 wherein said antibody comprises a monoclonal or polyclonal antibody.

Claim 13 (new): The method of claim 8 wherein Pro104 comprises SEQ ID NO: 2.

Claim 14 (new): A method of delivering a derivatized antibody to a gynecologic cancer cell comprising administering to the cell a derivatized antibody which specifically binds a Pro104 polypeptide.

Claim 15 (new): The method of claim 14 wherein said antibody is labeled with a fluorescent reagent, an enzyme, a paramagnetic ion or a radioisotope.

Claim 16 (new): The method of claim 14 wherein said antibody comprises a monoclonal or polyclonal antibody.

Attorney Docket No.: DEX-0176  
Inventors: Ali and Cafferkey  
Serial No.: 09/787,844  
Filing Date: August 6, 2001  
Page 6

Claim 17 (new): The method of claim 14 wherein Pro104 comprises SEQ ID NO: 2.

Claim 18 (new): A method of delivering a derivatized antibody to a gynecologic tumor comprising administering to the tumor a derivatized antibody which specifically binds a Pro104 polypeptide.

Claim 19 (new): The method of claim 18 wherein said antibody is labeled with a fluorescent reagent, an enzyme, a paramagnetic ion or a radioisotope.

Claim 20 (new): The method of claim 18 wherein said antibody comprises a monoclonal or polyclonal antibody.

Claim 21 (new): The method of claim 18 wherein Pro104 comprises SEQ ID NO: 2.